A phase II, randomized study of JMT101 in combination with irinotecan and SG001 versus regorafenib in patients with metastatic colorectal adenocarcinoma (mCRC).
Authors: Jianmin Xu, Wentao Tang, Xiugao Yang, Yang Yang, Qiwen Chen, Jianhong Cheng, Xuechao Wan, Yane Song, Mengke Li